About Alpha Tau Medical Ltd.
https://www.alphatau.comAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
CEO
Uzi Sofer
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 2
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
HIGHTOWER ADVISORS, LLC
Shares:686.55K
Value:$5.15M
HOYLECOHEN, LLC
Shares:269.09K
Value:$2.02M
LEVIN CAPITAL STRATEGIES, L.P.
Shares:204.71K
Value:$1.54M
Summary
Showing Top 3 of 37
About Alpha Tau Medical Ltd.
https://www.alphatau.comAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $-48.64M ▼ | $-11.69M ▼ | 0% | $-0.14 ▼ | $-10.45M ▼ |
| Q2-2025 | $0 | $9.65M ▲ | $-10.11M ▼ | 0% | $-0.13 ▼ | $-9.18M ▲ |
| Q1-2025 | $0 | $9.31M ▼ | $-8.69M ▲ | 0% | $-0.12 ▲ | $-9.31M ▼ |
| Q4-2024 | $0 | $10.27M ▲ | $-9.48M ▼ | 0% | $-0.14 ▼ | $-5.4M ▲ |
| Q3-2024 | $0 | $8.29M | $-6.92M | 0% | $-0.1 | $-8.02M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $72.21M ▼ | $104.69M ▼ | $27.11M ▲ | $77.58M ▼ |
| Q2-2025 | $79.7M ▲ | $110.95M ▲ | $24.33M ▼ | $86.62M ▲ |
| Q1-2025 | $51.64M ▼ | $80.93M ▼ | $24.6M ▲ | $56.33M ▼ |
| Q4-2024 | $59.6M ▼ | $86.2M ▼ | $23.54M ▲ | $62.67M ▼ |
| Q3-2024 | $65.22M | $90.73M | $21.33M | $69.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.69M ▼ | $0 | $0 | $0 | $-8.26M ▼ | $0 |
| Q2-2025 | $-10.11M ▼ | $0 | $0 | $0 | $7.03M ▲ | $0 |
| Q1-2025 | $-8.69M ▲ | $0 | $0 | $0 | $-8.75M ▼ | $0 |
| Q4-2024 | $-9.48M ▼ | $0 | $0 | $0 | $8.25M ▲ | $0 |
| Q3-2024 | $-6.92M | $0 | $0 | $0 | $2.85M | $0 |
CEO
Uzi Sofer
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 2
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
HIGHTOWER ADVISORS, LLC
Shares:686.55K
Value:$5.15M
HOYLECOHEN, LLC
Shares:269.09K
Value:$2.02M
LEVIN CAPITAL STRATEGIES, L.P.
Shares:204.71K
Value:$1.54M
Summary
Showing Top 3 of 37